Apoptosis sensitizers enhance cytotoxicity in hepatoblastoma cells (Q44448455)

3 December 2017

title

Apoptosis sensitizers enhance cytotoxicity in hepatoblastoma cells (English)

1 reference

3 December 2017

0 references

1 reference

Justus Lieber

1

1 reference

3 December 2017

Verena Ellerkamp

2

1 reference

3 December 2017

Julia Wenz

3

1 reference

3 December 2017

Bettina Kirchner

4

1 reference

3 December 2017

Steven W Warmann

5

1 reference

3 December 2017

Jörg Fuchs

6

1 reference

3 December 2017

Sorin Armeanu-Ebinger

7

1 reference

3 December 2017

publication date

1 February 2012

1 reference

Pediatric Surgery International

3 December 2017

published in

1 reference

3 December 2017

volume

28

1 reference

3 December 2017

issue

2

1 reference

3 December 2017

page(s)

149-159

1 reference

https://scigraph.springernature.com/pub.10.1007/s00383-011-2988-z

3 December 2017

exact match

0 references

cites work

Overview of the molecular bases of resistance to chemotherapy in liver and gastrointestinal tumours

1 reference

https://api.crossref.org/works/10.1007%2FS00383-011-2988-Z

Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB 94.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00383-011-2988-Z

Risk-adapted treatment for childhood hepatoblastoma. final report of the second study of the International Society of Paediatric Oncology--SIOPEL 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00383-011-2988-Z

MDR1 modulators improve the chemotherapy response of human hepatoblastoma to doxorubicin in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00383-011-2988-Z

Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00383-011-2988-Z

Mimicking the BH3 domain to kill cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00383-011-2988-Z

Gene expression profiling reveals signatures characterizing histologic subtypes of hepatoblastoma and global deregulation in cell growth and survival pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00383-011-2988-Z

Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00383-011-2988-Z

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00383-011-2988-Z

Bcl-2 family proteins and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00383-011-2988-Z

Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00383-011-2988-Z

Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00383-011-2988-Z

HA14-1, a small molecule inhibitor of Bcl-2, bypasses chemoresistance in leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00383-011-2988-Z

Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00383-011-2988-Z

Dual mechanisms of sHA 14-1 in inducing cell death through endoplasmic reticulum and mitochondria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00383-011-2988-Z

HA14-1 selectively induces apoptosis in Bcl-2-overexpressing leukemia/lymphoma cells, and enhances cytarabine-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00383-011-2988-Z

The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00383-011-2988-Z

Bcl-2 is a key regulator for the retinoic acid-induced apoptotic cell death in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00383-011-2988-Z

Ethyl-2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H- chromene-3-carboxylate (HA 14-1), a prototype small-molecule antagonist against antiapoptotic Bcl-2 proteins, decomposes to generate reactive oxygen species that induce apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00383-011-2988-Z

sHA 14-1, a stable and ROS-free antagonist against anti-apoptotic Bcl-2 proteins, bypasses drug resistances and synergizes cancer therapies in human leukemia cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00383-011-2988-Z

Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00383-011-2988-Z

TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00383-011-2988-Z

Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00383-011-2988-Z

TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and invasion in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00383-011-2988-Z

Chemotherapy in the treatment of locally advanced head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00383-011-2988-Z

The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00383-011-2988-Z

Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00383-011-2988-Z

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00383-011-2988-Z

The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00383-011-2988-Z

The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00383-011-2988-Z

Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00383-011-2988-Z

Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00383-011-2988-Z

Differential responses of proliferating versus quiescent cells to adriamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00383-011-2988-Z

Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma

21 January 2018

1 reference

12 December 2020

Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma

1 reference

12 December 2020

Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group

1 reference

12 December 2020

Development of a drug resistance model for hepatoblastoma

1 reference

12 December 2020

The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism.

1 reference

12 December 2020

Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study

1 reference

12 December 2020

Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma. Study Committee of the Cooperative Paediatric Liver Tumour Study HB89 of the German Society for Paediatric Oncology and Haematology

1 reference

12 December 2020

Cumulative toxicities from cisplatin therapy and current cytoprotective measures

1 reference

12 December 2020

Characterization of the continuous cell line HepT1 derived from a human hepatoblastoma.

1 reference

12 December 2020

Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2

1 reference

12 December 2020

10.1007/S00383-011-2988-Z

Identifiers

DOI

1 reference

3 December 2017

1 reference